Investigating the Safety and Efficacy of the Treatment With the Non-compliant Jade Balloon in TASC C and D Athero-occlusive Infra-inguinal Disease in Patients With Chronic Limb Threatening Limb Ischemia From SingaporE
NCT ID: NCT04534192
Last Updated: 2020-11-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
50 participants
INTERVENTIONAL
2020-08-01
2022-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
JADE balloon
Non-compliant high pressure JADE balloon for the treatment of infrainguinal stenotic occlusive or stenotic TASC C \& D lesions in patients with chronic limb threatening ischemia.
JADE Balloon
Suitable TASC C and D lesions will be treated with non-compliant high pressure JADE balloon.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
JADE Balloon
Suitable TASC C and D lesions will be treated with non-compliant high pressure JADE balloon.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patient has critical limb ischemia, presenting a score from 4 to 6 following the Rutherford classification
3. Patients must agree to return for all required post-index procedure follow-up visits.
4. Patient understands the nature of the procedure and provides written informed consent, prior to enrolment in the study
5. Patient has a projected life expectancy of at least 12 months and has not suffered a myocardial infarction within past 30 days
1. De novo and post-PTA re-stenotic lesions located in the superficial femoral, popliteal and tibial arteries suitable for endovascular therapy
2. The target lesion is located within the native SFA/popliteal/tibial artery
3. The length of the target lesion(s) is \> 100mm and considered as TASC C or D lesion according to the TASC II classification.
4. The target lesion has angiographic evidence of stenosis \> 50% or occlusion, which has been passed with standard guidewire manipulation and no other adjunctive devices have been used to prepare the lesion (example scoring balloon, rotablator, atherectomy device)
5. Target vessel diameter visually estimated is \>1.5mm and \< 6.5mm below the groin
6. Prior to enrolment, the guidewire has crossed the target lesion
7. Lesions in the treated segment may be continuous or may have gaps present between stenoses and occlusions
8. Inflow iliac, common femoral artery lesions can be treated during the same procedure using standard angioplasty and/or approved device/open surgery. These inflow lesions must be treated first prior to consideration of treatment of the distal lying lesions. The patient can be enrolled if the inflow lesions are treated with good embolization)
9. There is angiographic evidence of at least one- vessel-runoff through the ankle and into the foot, irrespective of whether or not outflow was re- established by means of previous endovascular intervention
Exclusion Criteria
2. Presence of a stent in the target lesion(s) that was placed during a previous procedure
3. The intervention is being performed in preparation for a planned amputation.
4. Untreated flow-limiting inflow lesions
5. Any previous surgery in the target vessel (including prior ipsilateral crural bypass)
6. Previous bypass surgery in the same limb
7. Patients with a history of Myocardial Infarction (MI), thrombolysis or angina within 30 days prior-index procedure.
8. Patients with a history of major disabling stroke within 3 months prior index procedure.
9. Patients with any type of previous or planned surgical or interventional procedure within 15 days prior- and/or within 30 days post-index procedure.
10. Untreatable lesion located at the distal outflow arteries
11. Patients with uncorrected bleeding disorders
12. Aneurysm located at the level of the SFA/popliteal artery
13. Non-atherosclerotic disease resulting in occlusion (e.g. embolism, Buerger's disease, vasculitis)
14. Any condition which prevents patient from complying with the study protocol or if patient has a life expectancy of \<1yr.
15. Major distal amputation (above the transmetatarsal) in the study limb or non-study limb
16. Patients with a presence or history of severe renal failure (Glomerular Filtration Rate (GFR) ≤ 30 ml/min) and is not dialysis dependent.
17. Neurotrophic ulcer or heel pressure ulcer or ulcer potentially involving calcaneus (index limb)
18. Episode of acute limb ischaemia within the previous 1 month
19. Use of thrombectomy, cutting balloon, lithotripsy, atherectomy or laser devices during procedure
20. Any patient considered to be hemodynamically unstable at onset of procedure
21. Patients with a known hypersensitivity or contraindication to aspirin, heparin, clopidogrel, or other anticoagulant/anti-platelet therapies or sensitivity to contrast media that cannot be adequately premedicated.
22. The patient is currently breast-feeding, pregnant or intends to become pregnant.
23. Subject receiving immunosuppression therapy, or has known serious immunosuppressive disease (e.g., human immunodeficiency virus), or has severe autoimmune disease that requires chronic immunosuppressive therapy (e.g., systemic lupus erythematosus, etc.) The patient should also not receive inhibitors of CYP3A (such as Itraconazole, and Erythromycin), or inducers of CYP3A (such as Rifampin) within 90 days following the procedure.
24. Patient is participating in another research study of a device, medication, biologic or other agent within 30 days which could in the opinion of the investigator affect the results of this study
25. Patients with any contraindications as mentioned in the Instructions for Use (IFU) of the Investigational Device.
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National University Hospital, Singapore
OTHER
Singapore General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tjun Yip Tang, MD
Role: PRINCIPAL_INVESTIGATOR
Singapore General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Singapore General Hospital
Singapore, , Singapore
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020/2425
Identifier Type: -
Identifier Source: org_study_id